Showing results (91-100 of 111) with videos related to
Sort By:
Pageof 12
Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz|September 15, 2020
[Rapid diagnosis of sexually transmitted infections : Joint statement of DSTIG, RKI, and PEI, as well as the reference centers for HIV, HBV, and HCV and consulting laboratories for Chlamydia, gonococci, and Treponema pallidum]Thomas Meyer, Josef Eberle, R Stefan Roß, et al.Pharmacogenetics and Genomics|November 16, 2011
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDSNeill J Liptrott, Sudeep Pushpakom, Christoph Wyen, et al.Experimental Neurology|August 24, 2014
Cytoplasmic HIV-RNA in monocytes determines microglial activation and neuronal cell death in HIV-associated neurodegenerationSimon Faissner, Björn Ambrosius, Kirsten Schanzmann, et al.Nature Medicine|May 29, 2012
The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma–associated herpesvirusAlexander S Hahn, Johanna K Kaufmann, Effi Wies, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 27, 2019
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel NodeUlrike Leiter, Rudolf Stadler, Cornelia Mauch, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|November 26, 2010
Influence of major HIV-1 protease inhibitor resistance mutations on CTL recognitionSandra M Mueller, Bernd M Spriewald, Silke Bergmann, et al.The Journal of Antimicrobial Chemotherapy|February 19, 2008
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsChristoph Wyen, Heidy Hendra, Martin Vogel, et al.AIDS (London, England)|January 20, 2026
Cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: 24-month outcomes in people with HIV-1Christoph Wyen, Celia Jonsson-Oldenbüttel, Sebastian Noe, et al.Eclinicalmedicine|December 8, 2025
Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus two NRTIs in adults naive to antiretroviral therapy (DOMINO): 24-week results from a randomised phase 2b studySamit R Joshi, Ezequiel Cordova, Essack Mitha, et al.Pageof 12